Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration
Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration
A study to examine the safety and potential effectiveness of human umbilical cord mesenchymal
 stem cells (hUMSCs) in adults who have suffered spontaneous cerebral hemorrhage in basal
 ganglia. The hypothesis is that hUMSCs will be safe and can improve neurological function
 after intracerebral hemorrhage so that improve the prognosis of patients.
Inclusion Criteria:

 -  Male or female participants between 30 and 75 years of age, diagnosed of spontaneous
 basal ganglia hemorrhage by imaging (CT, CTA, etc.) with a volume from 10 ml to 60 ml
 calculated by ABC/2 formula.

 -  Within 5 days from onset to operation, and no improvement.

 -  Glasgow Coma Scale (GCS) score of 9 to 15.

 -  With dysfunction such as hematoma-related motor aphasia, sensory aphasia, hemiplegic
 limb muscle strength≤grade 3.

 -  Modified Rankin scale (mRS) score≤1 in past medical history.

 -  Women of reproductive age have negative pregnancy tests.

 -  The participants or the legal guardian/representative who are suitable and willing to
 participate in the clinical trial and can cooperate to complete the follow-ups.

 Exclusion Criteria:

 -  Imaging-based diagnosis of cerebrovascular abnormalities such as ruptured aneurysm,
 arteriovenous malformation AVM and moyamoya disease as well as hemorrhagic
 transformation of ischemic infarct and recent recurrence (within 1 year) of cerebral
 hemorrhage.

 -  In the sequela stage of cerebral trauma.

 -  Hematoma involves other structures including but not limited to the thalamus and
 midbrain or complicated with intraventricular hemorrhage.

 -  With neurologic impairment before cerebral hemorrhage onset.

 -  Participants receiving anticoagulant or antiplatelet therapy.

 -  The disease progresses quickly. Manifestation of cerebral herniation such as bilateral
 dilated pupil, disappearance of light reflex, and unstable vital signs.

 -  Active stage of infectious diseases including but not limited to HIV, hepatitis B, and
 C.

 -  History of poorly controlled seizures.

 -  History of severe co-morbidity (including but not limited to hepatic, renal,
 gastrointestinal, respiratory, cardiovascular, endocrine, immune and/or hematological
 disorders) which may affect the outcome assessment. Coagulation dysfunction INR >1.4,
 PTT>37 seconds, thrombocytopenia (PLT<8×10^9/L), serum creatinine exceeded the upper
 limit of normal by 1.4 times, serum ALT >150U/L, and/or serum total bilirubin
 >1.6mg/dl.

 -  Participants with a mechanical heart valve. Biological valves are acceptable.

 -  Participants with a risk of embolism (including but not limited to a history of left
 heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis or
 subacute bacterial endocarditis). Atrial fibrillation without mitral stenosis is
 acceptable.

 -  May be pregnant in the near future or already pregnant.

 -  Enrolled in this clinical trial or participating in other interventional medical
 research or clinical trials at the same time.

 -  Participants difficult to follow up or with poor compliance due to various reasons
 (including but not limited to geographical and social factors, drug or alcohol abuse).

 -  Participants or the legal guardian/representative is unable or unwilling to give the
 written informed consent.

 -  Vulnerable groups (including but not limited to mental retardation, abuse, inability
 to fully exercise informed consent).

 -  Any subject that the researchers think is not suitable for enrollment.